<DOC>
	<DOCNO>NCT01306890</DOCNO>
	<brief_summary>The purpose study quantify risk cerebrovascular event ( CVEs ) follow sipuleucel-T ( PROVENGE® ) therapy , follow subject survival .</brief_summary>
	<brief_title>A Registry Sipuleucel-T Therapy Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>Subjects receive product describe sipuleucel-T approved label . The registry strictly observational thus additional clinical visit laboratory test conduct beyond normal clinical practice . Investigators ask record information become available normal course clinical management .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>subject must least 18 year age subject advanced prostate cancer receive sipuleucelT underwent first leukapheresis manufacture sipuleucelT ≤ 6 month prior enrollment subject must understand sign inform consent form</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>